The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
"Up to 32% of incident dementia cases could be attributable to clinically significant audiometric hearing loss," revealing the potential impact of treating hearing impairment for dementia prevention in older adults.
SAHaRA trial investigators compared a liberal (transfusion at hemoglobin levels of 10 g/dL or lower) and a restrictive (transfusion at 8 g/dL or lower) red-cell tranfusion strategy among critically ill patients with acute aneurysmal subarachnoid hemorrhage (SAH) and anemia.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.
“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”